Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

CVKD Cadrenal Therapeutics Inc

19,86

0,11 (0,56%)

Zuletzt aktualisiert: 16:12:09

Verzögert um 15 Minuten

Form EFFECT - Notice of Effectiveness

Cadrenal Therapeutics (NASDAQ:CVKD)
Historical Stock Chart
Von Jan 2025 bis Feb 2025

Click Here for more Cadrenal Therapeutics Charts.

Cadrenal Therapeutics (NASDAQ:CVKD)
Historical Stock Chart
Von Feb 2024 bis Feb 2025

Click Here for more Cadrenal Therapeutics Charts.

News Cadrenal Therapeutics Inc

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
Donnerstag 6 Februar 2025 (2 Stunden vor) • Business Wire

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
Mittwoch 5 Februar 2025 (1 Tag vor) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Montag 3 Februar 2025 (3 Tage vor) • Edgar (US Regulatory)

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Donnerstag 9 Januar 2025 (4 Wochen vor) • Business Wire

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications
Dienstag 31 Dezember 2024 (1 Monat vor) • Business Wire

Form S-8 - Securities to be offered to employees in employee benefit plans
Montag 23 Dezember 2024 (1 Monat vor) • Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]
Freitag 20 Dezember 2024 (2 Monate vor) • Edgar (US Regulatory)

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings
Mittwoch 18 Dezember 2024 (2 Monate vor) • Business Wire

Form 424B3 - Prospectus [Rule 424(b)(3)]
Montag 25 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Form EFFECT - Notice of Effectiveness
Montag 25 November 2024 (2 Monate vor) • Edgar (US Regulatory)

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
Dienstag 19 November 2024 (3 Monate vor) • PR Newswire (US)

Form S-3 - Registration statement under Securities Act of 1933
Donnerstag 14 November 2024 (3 Monate vor) • Edgar (US Regulatory)

Weitere Cadrenal Therapeutics Inc News-Artikel

Check Point Software Tec...

Societe Generale Effekten

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen